Production (Stage)
D
BioCryst Pharmaceuticals, Inc. BCRX
$10.59 $0.201.93% NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

03/31/2025 12/31/2024 09/30/2024 06/30/2024 03/31/2024
Net Income 32.00K -26.80M -14.03M -12.67M -35.38M
Total Depreciation and Amortization 331.00K 2.08M 311.00K 320.00K 306.00K
Total Amortization of Deferred Charges -- -- -- -- --
Total Other Non-Cash Items 34.25M 30.84M 31.10M 29.28M 29.91M
Change in Net Operating Assets -62.13M -11.33M -9.13M -18.30M -48.52M
Cash from Operations -27.52M -5.21M 8.25M -1.37M -53.68M
Capital Expenditure -143.00K -675.00K -59.00K -155.00K -235.00K
Sale of Property, Plant, and Equipment -- -- -- -- --
Cash Acquisitions -- -- -- -- --
Divestitures -- -- -- -- --
Other Investing Activities 27.24M 18.47M 8.55M -2.29M 28.99M
Cash from Investing 27.10M 17.80M 8.49M -2.45M 28.76M
Total Debt Issued -- -- -- -- --
Total Debt Repaid -516.00K -356.00K -556.00K -402.00K -390.00K
Issuance of Common Stock 2.40M -- 2.09M 276.00K 1.69M
Repurchase of Common Stock -- -581.00K -- -- --
Issuance of Preferred Stock -- -- -- -- --
Repurchase of Preferred Stock -- -- -- -- --
Total Dividends Paid -- -- -- -- --
Other Financing Activities -1.35M -3.08M -261.00K -1.84M -2.35M
Cash from Financing 529.00K -4.02M 1.27M -1.97M -1.05M
Foreign Exchange rate Adjustments 451.00K -1.30M 851.00K -143.00K -340.00K
Miscellaneous Cash Flow Adjustments -- -- -- -- --
Net Change in Cash 558.00K 7.26M 18.86M -5.93M -26.32M